1.33 USD
▼-0.18-11.92%
盘后 1.35 +1.50%
2026-11-20
市值
$66.30M
市盈率
—
EPS
-0.18
股息率
—
52 周区间
1.30 – 48.91
成交量
49.40K
Beta
—
目标价
7.50
52W 低 1.3052W 高 48.91
价格走势
公司简介
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was found...